Introduction: Alphabet’s life sciences subsidiary, Verily, is undergoing a significant strategic shift, marked by the closure of its medical device program and a reallocation of resources towards artificial intelligence (AI) and data infrastructure. This move signals a broader trend within Alphabet to prioritize AI development and deployment across its various ventures, impacting Verily’s operational focus…